Skip to main content

Table 1 Immune checkpoints expression in liver cancers

From: Immune checkpoint therapy in liver cancer

Cancer type Number TNM Stage (I + II / III + IV) Tumor differentiation (I + II / III + IV) Tumor size (cm) Immune checkpoints Cellular expression Year Reference
Human HCC 217 (tumor samples) Operable, resected 101 (46%)/ 116 (53%) 7.26 (1.0–2.5) PD-L1/PD-1 neoplastic and inflammatory cells 2016 [24]
Human HCC 176 97/52 112/64 5.3 (PD-L1 low)/4.9 (PD-L1 high) PD-L1 CD68+ macrophages 2016 [27]
Human HCC 90 Operable, resected 73/17 4.2 (1.3–15) PD-L1 peritumoral hepatocytes 2017 [25]
Human HCC 294 59/87 140/6 110(<5) /36(≥5) PD-L1/PD-1 and CTLA-4 tumor infiltrating 2017 [26]
Human HCC 69 35/34 50/19 7/21(Tim-3 low)/17/24 (Tim-3 high) Tim-3 CD14+ monocytes 2015 [28]
Human HCC 171 100/71 NR 98/73 PD-1 and Tim-3 neoplastic and inflammatory cells 2016 [29]
Human ICC 31 9/22 13/18 20 (<5) / 11 (>5) PD-L1 and PD-1 neoplastic and inflammatory cells 2009 [38]
Human ICC 27 16/11 19/8 NR PD-L1 ICC cells 2016 [36]
  1. HCC hepatocellular carcinoma, ICC Intrahepatic cholangiocarcinoma, NR not reported